Artículo especialConsenso sobre guías de tratamiento de los glioblastomas elaborado por el Grupo de Trabajo de Neurooncología (GTNO) de la SENECGlioblastoma treatment guidelines: Consensus by the Spanish Society of Neurosurgery Tumor Section
Section snippets
Introducción
El tratamiento de los glioblastomas (GMB) comienza en la mayor parte de los pacientes con una cirugía, ya sea para la extirpación tumoral, ya sea para la obtención de tejido con el que alcanzar un diagnóstico histológico.
A pesar de que los GBM son tumores agresivos y el pronóstico es malo, los pacientes se pueden beneficiar de tratamientos que mejoren no solo la supervivencia global sino también la calidad de vida1.
Con el fin de obtener el máximo beneficio de estos tratamientos cada paciente
Material y métodos
Se clasificaron las distintas disciplinas terapéuticas para el tratamiento de los gliomas malignos en cirugía, quimioterapia y radioterapia (RT), valorando su papel en primera línea y en líneas posteriores, así como en pacientes ancianos. Además, se estudiaron las opciones de inmunoterapia, ensayos clínicos y clasificación histológica y molecular actual, junto a una revisión de las nuevas técnicas neuroquirúrgicas para la cirugía de los tumores cerebrales. Se encargó a un miembro del grupo de
Resultados
A continuación se resumen los contenidos de cada área.
Conclusiones
El grupo de tumores de la Sociedad Española de Neurocirugía ha elaborado esta guía de consenso sobre el tratamiento de los gliomas de alto grado basado en la mejor evidencia disponible en la literatura y en la experiencia de neurocirujanos que de forma habitual tratan estos tumores, con el objetivo de que sirvan para la consulta y resulten de ayuda en la toma de decisiones.
Financiación
La presente investigación no ha recibido ayudas específicas provenientes de agencias del sector público, sector comercial ni entidades sin ánimo de lucro.
Conflicto de intereses
Los autores declaran no tener ningún conflicto de intereses.
Bibliografía (79)
- et al.
Patterns of management and outcomes of unifocal versus multifocal glioblastoma
J Clin Neurosci Off J Neurosurg Soc Australas
(2020) - et al.
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial
Lancet Oncol
(2012) - et al.
Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients
Int J Radiat Oncol Biol Phys
(2008) - et al.
How safe are carmustine wafers?
Rev Neurol (Paris)
(2018) - et al.
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
J Exp Clin Cancer Res.
(2019) - et al.
Rindopepimut with temozolomide for patients with newly diagnosed EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial
Lancet Oncol.
(2017) - et al.
Impact of Resecting Radiation Necrosis and Pseudoprogression on Survival of Patients with Glioblastoma
World Neurosurg.
(2016) - et al.
Patterns of re-irradiation for recurrent gliomas and validation of a prognostic score
Radiother Oncol
(2019) - et al.
A retrospective review of re-irradiating patients’ recurrent high-grade gliomas
Clin Oncol (R Coll Radiol)
(2018) - et al.
Re-irradiation for malignant glioma: Toward patient selection and defining treatment parameters for salvage
Adv Radiat Oncol
(2018)
Toxicity and efficacy of re-irradiation of high-grade glioma in a phase I dose- and volume escalation trial
Radiother Oncol
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): A randomised controlled phase 2 trial
Lancet Oncol
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas: The Polymer-brain Tumor Treatment Group
Lancet
Prognostic and predictive factors in high-grade gliomas: Experience at our institution
Neurocirugia (Astur)
Optimal management of elderly patients with glioblastoma
Cancer Treat Rev
Assessment of the impact of glioma diagnostic reclassification following the new 2016 WHO classification on a series of cases
Neurocirugia (Astur)
Isocitrate dehydrogenase type I mutation as a prognostic factor in glioblastoma and a literature review
Neurocirugia (Astur)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial
Lancet Oncol
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): A randomised, open-label, phase 3 trial
Lancet
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial
Lancet Oncol
Intraoperative Computed Tomography in Cranial Neurosurgery
Neurosurg Clin N Am
Development of a fluorescein operative microscope for use during malignant glioma surgery: A technical note and preliminary report
Surg Neurol.
Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain
Neuro Oncol.
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
Lancet Oncol
Association of the extent of resection with survival in glioblastoma a systematic review and meta-Analysis
JAMA Oncol
An extent of resection threshold for newly diagnosed glioblastomas
J Neurosurg
Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma
Neuro Oncol
Impact of removed tumor volume and location on patient outcome in glioblastoma
J Neurooncol
A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival
J Neurosurg
Impact of intraoperative stimulation brain mapping on glioma surgery outcome: A meta-analysis
J Clin Oncol
Multiple high-grade gliomas: Epidemiology, management, and outcome. A systematic review and meta-analysis
Neurosurg Rev
Patterns of care and clinical outcome in assumed glioblastoma without tissue diagnosis: A population-based study of 131 consecutive patients
PLoS One
Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the Scandinavian Glioblastoma Study Group
Cancer
Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial
J Clin Oncol.
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
N Engl J Med
Short-course radiation plus temozolomide in elderly patients with glioblastoma
N Engl J Med
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma
N Engl J Med
A randomized trial of bevacizumab for newly diagnosed glioblastoma
N Engl J Med
Gliadel wafer in initial surgery for malignant glioma: Long-term follow-up of a multicenter controlled trial
Acta Neurochir (Wien)
Cited by (6)
Ultrasound-triggered drug delivery for glioma therapy through gambogic acid-loaded nanobubble-microbubble complexes
2022, Biomedicine and PharmacotherapyCitation Excerpt :The malignant degree of brain glioma is very high [42]. Glioma brings a heavy burden to the family and society [1,43]. Many methods are used to treat gliomas, the most common of which is chemotherapy [2].
A Gambogic Acid-Loaded Delivery System Mediated by Ultrasound-Targeted Microbubble Destruction: A Promising Therapy Method for Malignant Cerebral Glioma
2022, International Journal of NanomedicineA thoracic outlet syndrome that concealed a glioblastoma. Findings from a case report
2021, Medicina (Lithuania)